公开(公告)号：US20140348842A1

公开(公告)日：2014-11-27

申请号：US14264791

申请日：2014-04-29

申请人： The Brigham and Women's Hospital, Inc. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Vijay K. Kuchroo ,  Terry Strom ,  Eugene K. Cha ,  Sumone Chakravarti ,  Catherine Sabatos ,  Chen Zhu ,  Xin Xiao Zheng ,  Alberto Sanchez-Fueyo

IPC分类号： C07K16/18

CPC分类号： C07K16/18 ,  C07K14/4713 ,  C07K14/70503 ,  C07K16/28 ,  C07K2319/30 ,  G01N33/505

摘要： The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.

摘要翻译： 本发明涉及分离的多肽和编码多肽的核酸，其包含tim-3 IgV结构域和tim-3细胞内结构域，其中所述多肽不包含tim-3粘蛋白结构域或tim-3跨膜结构域。 此外，本发明涉及调节受试者中的免疫应答的方法，包括向受试者施用治疗有效量的调节tim-3活性的药剂。 免疫反应包括但不限于免疫耐受性，移植耐受性，Th1应答和Th2应答。

公开(公告)号：US09346876B2

公开(公告)日：2016-05-24

申请号：US14264791

申请日：2014-04-29

申请人： The Brigham and Women's Hospital, Inc. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Vijay K. Kuchroo ,  Terry Barton Strom ,  Eugene K. Cha ,  Sumone Chakravarti ,  Catherine Anne Sabatos-Peyton ,  Chen Zhu ,  Xin Xiao Zheng ,  Alberto Sanchez-Fueyo

IPC分类号： C07K16/28 ,  C07K16/18 ,  C07K14/47 ,  C07K14/705 ,  G01N33/50

CPC分类号： C07K16/18 ,  C07K14/4713 ,  C07K14/70503 ,  C07K16/28 ,  C07K2319/30 ,  G01N33/505

摘要： The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.

摘要翻译： 本发明涉及分离的多肽和编码多肽的核酸，其包含tim-3 IgV结构域和tim-3细胞内结构域，其中所述多肽不包含tim-3粘蛋白结构域或tim-3跨膜结构域。 此外，本发明涉及调节受试者中的免疫应答的方法，包括向受试者施用治疗有效量的调节tim-3活性的药剂。 免疫反应包括但不限于免疫耐受性，移植耐受性，Th1应答和Th2应答。

公开(公告)号：US20130183688A1

公开(公告)日：2013-07-18

申请号：US13670096

申请日：2012-11-06

申请人： The Brigham and Women's Hospital, Inc. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Vijay K. Kuchroo ,  Terry Strom ,  Eugene K. Cha ,  Sumone Chakravarti ,  Catherine Sabatos ,  Chen Zhu ,  Xin Xiao Zheng ,  Alberto Sanchez-Fueyo

IPC分类号： G01N33/50

CPC分类号： C07K16/18 ,  C07K14/4713 ,  C07K14/70503 ,  C07K16/28 ,  C07K2319/30 ,  G01N33/505

摘要： The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.

摘要翻译： 本发明涉及分离的多肽和编码多肽的核酸，其包含tim-3 IgV结构域和tim-3细胞内结构域，其中所述多肽不包含tim-3粘蛋白结构域或tim-3跨膜结构域。 此外，本发明涉及调节受试者中的免疫应答的方法，包括向受试者施用治疗有效量的调节tim-3活性的药剂。 免疫反应包括但不限于免疫耐受性，移植耐受性，Th1应答和Th2应答。

公开(公告)号：US10513540B2

公开(公告)日：2019-12-24

申请号：US14418726

申请日：2013-07-30

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Richard S. Blumberg ,  Vijay K. Kuchroo ,  Yu-Hwa Huang ,  Chen Zhu ,  Ana C. Anderson

IPC分类号： C07K7/06 ,  C07K7/08 ,  C07K16/28 ,  C07K16/30 ,  A61K38/10 ,  A61K39/395 ,  C07K14/705 ,  A61K39/00

摘要： Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.

公开(公告)号：US20150284459A1

公开(公告)日：2015-10-08

申请号：US14437354

申请日：2013-10-30

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Vijay K. Kuchroo ,  Chen Zhu ,  Ana Carrizosa Anderson

IPC分类号： C07K16/24 ,  C07K16/18 ,  A61K38/20 ,  A61K31/713 ,  A61K38/17

CPC分类号： C07K16/244 ,  A61K31/713 ,  A61K38/1709 ,  A61K38/1793 ,  A61K38/20 ,  C07K14/47 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/18 ,  C07K2317/75 ,  C07K2317/76 ,  C12N5/0636 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/16 ,  C12N2501/2303 ,  C12N2501/2327

摘要： Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i.e., inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.

摘要翻译： 本文描述的是包含IL-27或NFIL-3调节剂（即抑制剂或活化剂）的新型组合物，以及使用这些试剂靶向细胞如功能耗尽或无应答免疫细胞以及调节TIM-3活性或表达的方法。 这些组合物，方法和用途可用于治疗慢性免疫病症，例如持续感染，癌症和自身免疫性疾病。

公开(公告)号：US20170058026A1

公开(公告)日：2017-03-02

申请号：US15339218

申请日：2016-10-31

申请人： The Brigham and Women's Hospital, Inc.

发明人： Vijay K. Kuchroo ,  Chen Zhu ,  Ana Carrizosa Anderson

IPC分类号： C07K16/24 ,  C12N15/113

CPC分类号： C07K16/244 ,  A61K31/713 ,  A61K38/1709 ,  A61K38/1793 ,  A61K38/20 ,  C07K14/47 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/18 ,  C07K2317/75 ,  C07K2317/76 ,  C12N5/0636 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/16 ,  C12N2501/2303 ,  C12N2501/2327

摘要： Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.

摘要翻译： 本文描述了包含IL-27或NFIL-3调节剂（即抑制剂或活化剂）的新型组合物，以及使用这些试剂靶向细胞如功能性耗尽或无应答的免疫细胞以及调节TIM-3活性或表达的方法。 这些组合物，方法和用途可用于治疗慢性免疫病症，例如持续感染，癌症和自身免疫性疾病。

公开(公告)号：US20150225457A1

公开(公告)日：2015-08-13

申请号：US14418726

申请日：2013-07-30

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Richard S. Blumberg ,  Vijay K. Kuchroo ,  Yu-Hwa Huang ,  Chen Zhu ,  Ana C. Anderson

IPC分类号： C07K7/08 ,  A61K38/10 ,  A61K39/395 ,  C07K14/705

摘要： Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.

摘要翻译： 本文描述了用于调节T细胞耐受性的组合物和方法，其可以通过同时增强或抑制CEACAM1 / TIM3相互作用而被上调或下调。 如本文所述，CEACAM1是TIM3的直接配体，反之亦然的发现已经以顺式和反式表示。 此外，如本文所示，CEACAM1和TIM3在T细胞活化过程中共调节。